25 October 2024
25 October 2024
Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of Wegovy and Ozempic.
The committee voted to lower the recommended age for MSD’s Capvaxive and Pfizer’s Prevnar 20 to 50 years down from 65.
The deal includes potential milestone payments of up to $1.3bn for Modifi shareholders.
At CPHI Europe, an expert discussed the significance of implementing effective AI strategies to improve nutraceutical products.
Treating opioid addiction will be worth $2.4bn by 2033, driven by diagnoses in the eight major world markets.
The initiative aligns with Takeda's commitment to achieve net zero greenhouse gas emissions by 2035.
Richter will receive an upfront cash payment of $25m, with potential for further future payments
The company will use the funds to advance its pipeline of cancer-targeting preclinical candidates to the “clinic-ready” stage.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
